This article was originally published in The Gray Sheet
Mountain View, Calif., aesthetics device maker announces 510(k) clearance July 2 of its Fraxel re:pair laser with Fractional Deep Dermal Ablation for ablation, coagulation and skin resurfacing based on data from an ongoing, 200-patient, 10-site clinical trial. In the first phase of the trial, over 75% of patients treated with Fraxel re:pair showed improved appearance of rhytids, vascular dyschromia, pigmentation and skin laxity. Two later phases are evaluating the device for scar treatment. Reliant's other lasers on the market include Fraxel re:store for skin resurfacing and scar and wrinkle treatment, and Fraxel re:fine for gentle skin rejuvenation...
You may also be interested in...
Aesthetic laser manufacturer Reliant Technologies will launch its Fraxel Re:pair system for treatment of severe skin conditions in the first quarter of 2008, supported by the proceeds of a proposed initial public stock offering of up to $95 million
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.